Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2012-A00185-38 | Other Identifier | ANSM |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of this study is to compare the efficacy of unilateral and bilateral neuromodulation tests at 1 month.
The secondary objectives of this study are to compare the following elements between a group of patients undergoing unilater modulation tests (standard procedure) and a group of patients undergoing bilateral neuromodulation tests (experimental procedure) (at 1 month): Pollakiuria, pad use, urge incontinence, symptom severity, % of patients not eligible for an implant, debimetry, tolerance, complications, quality of life.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Unilateral testing | Active Comparator | Following standard procedures, patients in this group will have unilateral testing for neuromodulation of the sacral nerves. Intervention: Unilateral electrode placement and testing |
|
| Bilateral testing | Experimental | Patients in this group will have bilateral testing for neuromodulation of the sacral nerves. Intervention: Bilateral electrode placement and testing |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Unilateral electrode placement and testing | Procedure | An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device. |
| Measure | Description | Time Frame |
|---|---|---|
| Success rate | "Success" is defined as a >= 50% improvement in at least one of the following symtoms: pollakiuria, number of urge incontinence episodes with incontinence, number of urge incontinence episodes. | 1 month |
| Measure | Description | Time Frame |
|---|---|---|
| presence/absence: 50% reduction in the number of daily mictions | 1 month | |
| presence/absence: 50% reduction in the number of pads/protections used per day | 1 month | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Laurent Wagner, MD | Centre Hospitalier Universitaire de Nīmes | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Clinique Beau Soleil | Montpellier | 34070 | France | |||
| CHU de Nantes - Hôtel Dieu |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32835443 | Result | Wagner L, Alonso S, Le Normand L, Faix A, Kabani S, Castelli C, Game X, Cornu JN, Bey E. Unilateral versus bilateral sacral neuromodulation test in the treatment of refractory idiopathic overactive bladder: A randomized controlled pilot trial. Neurourol Urodyn. 2020 Nov;39(8):2230-2237. doi: 10.1002/nau.24476. Epub 2020 Aug 24. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Bilateral electrode placement and testing | Procedure | Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device. |
|
| presence/absence: 50% reduction in the number of urge incontinence episodes per day |
| 1 month |
| presence/absence: 50% reduction in the number of urge incontinence episodes with incontinence per day | 1 month |
| Symptom severity as measured by the MHU score | MHU = Mesure Hanicap Urinaire | 1 month |
| Yes/no: the patient was eligible for an implant | 1 month |
| debimetry: flow rate per voiding | 1 month |
| debimetry: urinary volume per voiding | 1 month |
| Visual analog scale for pain at the implantation site | 1 month |
| Visual analog scale for pain due to neuro stimulation (pain in legs or buttocks) | 1 month |
| Presence/absence of infection of the implant or electrode | 1 month |
| Change in quality of life: IQoL score | baseline to 1 month |
| Change in quality of life: KHQ score | baseline to 1 month |
| Change in quality of life: SF 36 score | baseline to 1 month |
| Nantes |
| 44093 |
| France |
| CHU de Nîmes - Hôpital Universitaire Carémeau | Nîmes | 30029 | France |
| APHP - Groupe Hospitalier Pitié-Salpetrière | Paris | 75651 | France |
| CHU de Rouen - Hôpital Charles Nicolle | Rouen | 76031 | France |
| CHRU de Toulouse - Hôpital de Rangueil | Toulouse | 31059 | France |
| ID | Term |
|---|---|
| D053201 | Urinary Bladder, Overactive |
| ID | Term |
|---|---|
| D001745 | Urinary Bladder Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided